文献速递淋巴瘤

循环肿瘤DNA追踪未经治疗的高中危/高危弥漫大B细胞淋巴瘤的演化

Tracking the evolution of untreated high-intermediate/high-risk diffuse large B-cell lymphoma by circulating tumour DNA.
PubMed 文献 · Br J Haematol · 2021-10-19

研究对38例高中危/高危弥漫大B细胞淋巴瘤患者基线肿瘤组织和血浆进行靶向测序(cSMART法)分析ctDNA,并纵向采集血样。结果显示ctDNA与肿瘤组织突变谱一致性良好,治疗前TP53或B2M突变预示不良预后,动态监测中ctDNA水平升高及KMT2D突变状态变化可预测疾病进展。

要点

  • 治疗前TP53或B2M突变预示高中危/高危DLBCL患者不良预后
  • ctDNA与肿瘤组织突变谱一致性良好,且可检出更多突变位点
  • 动态监测ctDNA水平升高及KMT2D突变状态变化可预测疾病进展

核心结论

  • ctDNA是检测DLBCL突变谱的有前景方法,可作为疾病监测和预测临床复发的生物标志物。

研究设计与样本

  • 研究纳入38例高中危/高危DLBCL患者,基线评估17份肿瘤活检组织和38份血浆样本,治疗期间纵向采集血样。
  • 采用基于基因面板的靶向测序,通过循环单分子扩增和重测序技术(cSMART)分析ctDNA。

主要发现

  • ctDNA与配对肿瘤组织突变谱一致性良好,但ctDNA样本检出更多突变位点。
  • 治疗前TP53或B2M突变预示不良预后。
  • 动态血样分析证实ctDNA可用于实时评估治疗反应,ctDNA水平升高和KMT2D突变状态变化可预测疾病进展。

临床怎么用

  • 可考虑对高中危/高危DLBCL患者治疗前进行ctDNA检测TP53和B2M突变以辅助预后分层。
  • 治疗期间动态监测ctDNA水平及KMT2D突变状态,有助于实时评估疗效和预警疾病进展。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Diffuse large B-cell lymphoma (DLBCL) is a highly heterogenous malignancy, early identification of patients for relapse remains challenging. The potential to non-invasively monitor tumour evolutionary dynamics of DLBCL needs to be further established. In the present study, 17 tumour biopsy and 38 plasma samples from 38 patients with high-intermediate/high-risk DLBCL were evaluated at baseline. Longitudinal blood samples were also collected during therapy. Circulating tumour DNA (ctDNA) was analysed using targeted sequencing based on a gene panel via a recently developed methodology, circulating single-molecule amplification and re-sequencing technology (cSMART). We found that the most frequently mutated genes were tumour protein p53 (TP53; 42·1%), histone-lysine N-methyltransferase 2D (KMT2D; 28·9%), caspase recruitment domain family member 11 (CARD11; 21·1%), cAMP response element-binding protein binding protein (CREBBP; 15·8%), β2 -microglobulin (B2M; 15·8%), and tumour necrosis factor alpha-induced protein 3 (TNFAIP3; 15·8%). The mutation profiles between ctDNA and matched tumour tissue showed good concordance; however, more mutation sites were detected in ctDNA samples. Either TP53 or B2M mutations before treatment predicted poor prognosis. Analysis of dynamic blood samples confirmed the utility of ctDNA for the real-time assessment of treatment response and revealed that the increases in ctDNA levels and changes in KMT2D mutation status could be useful predictors of disease progression. Our present results suggest that ctDNA is a promising method for the detection of mutation spectrum and serves as a biomarker for disease monitoring and predicting clinical recurrence.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Zhang S, Zhang T, Liu H, et al. Tracking the evolution of untreated high-intermediate/high-risk diffuse large B-cell lymphoma by circulating tumour DNA. Br J Haematol. 2021. PMID: 34664256. doi:10.1111/bjh.17894

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。